SRR934830
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 20.17082785808147
- age_years
- 54
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.687
- INTERFERON_GAMMA_RESPONSE+0.590
- ALLOGRAFT_REJECTION+0.469
- G2M_CHECKPOINT+0.460
- MITOTIC_SPINDLE+0.443
- IL6_JAK_STAT3_SIGNALING+0.436
- CHOLESTEROL_HOMEOSTASIS+0.428
- PROTEIN_SECRETION+0.410
- E2F_TARGETS+0.399
- IL2_STAT5_SIGNALING+0.372
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.451
- KRAS_SIGNALING_DN-0.320
- SPERMATOGENESIS-0.265
- MYOGENESIS-0.221
- ESTROGEN_RESPONSE_EARLY-0.127
- HEDGEHOG_SIGNALING-0.121
- ESTROGEN_RESPONSE_LATE-0.116
- XENOBIOTIC_METABOLISM-0.064
- UV_RESPONSE_UP-0.045
- APICAL_SURFACE-0.036
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934832 | — | — | 0.928 |
| 2 | 6292335B-7CBB-45BE-AA2A-B39FFDA8768D | — | — | 0.924 |
| 3 | SRR934942 | — | — | 0.919 |
| 4 | B4E10042-052D-4DC4-BC94-FF1D5D4632C0 | — | — | 0.902 |
| 5 | SRR934833 | — | — | 0.893 |
| 6 | AD62B8A4-6AB8-4C99-80F5-98A1C085027D | — | — | 0.887 |
| 7 | 1C62E679-3A4E-4D10-8BFB-5BFBF2A3B4B6 | — | — | 0.885 |
| 8 | 722B7A0F-BF34-4368-8CFF-944FCBC7DAC4 | — | — | 0.884 |
| 9 | 4942E435-61E6-4A43-B031-4E08F0B41186 | — | — | 0.883 |
| 10 | 5C40F9B6-4A54-4861-9DE5-8852BF4B13E7 | — | — | 0.883 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.687 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.590 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.469 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.460 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.443 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.436 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.428 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.410 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.399 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.372 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.370 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.324 | Inavolisib | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.294 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.291 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.264 | Inavolisib | — uncovered |
| PEROXISOME | 0.243 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.242 | Inavolisib | — uncovered |
| APOPTOSIS | 0.229 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.224 | Inavolisib | — uncovered |